Vandetanib for the treatment of metastatic Medullary thyroid cancer

Clinical Medicine Insights: Oncology

Volumn 6, Issue , 2012, Pages 243-252

  Degrauwe, Nils ^a   Sosa, Julie Ann ^b   Roman, Sanziana ^b   Deshpande, Hari A ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b YALE CANCER CENTER   (United States)

Author keywords

Medullary thyroid cancer; RET; Vandetanib

Indexed keywords

BEVACIZUMAB; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; IRINOTECAN; OXALIPLATIN; PEMETREXED; PLACEBO; PROTEIN RET; SUNITINIB; TRANSFORMING GROWTH FACTOR ALPHA; VANDETANIB; VASCULOTROPIN RECEPTOR;

ACUTE HEART FAILURE; ASPIRATION PNEUMONIA; BRAIN ISCHEMIA; BREAST CANCER; CANCER INHIBITION; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG COST; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; META ANALYSIS (TOPIC); METASTASIS; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY ARREST; RESPIRATORY FAILURE; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOLID TUMOR; STAPHYLOCOCCAL BACTEREMIA; STEVENS JOHNSON SYNDROME; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TIME TO MAXIMUM PLASMA CONCENTRATION; TORSADE DES POINTES;

EID: 84863924901     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S7999     Document Type: Review

References (64)

1. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clinical Endocrinology. 2004;61:299-310.
2. Modigliani E, Cohen R, Crampos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clinical Endocrinology. 1998;48(3):265-73.
3. Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathological variables. Cancer. 1996;77(8):1556-65.
4. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107(9):2134-42.
5. Matuszczyk A, Petersenn S, Bockisch A, et al. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res. 2008;40(3):210-3.
6. Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C, Schlumberger M. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU dacarbazine. British Journal of Cancer. 2000;83(6):715-71.
7. Fersht N, Vini L, A'Hern R, Harmer C. The role of radiotherapy in the management of elevated calcitonin after surgery for medullary thyroid cancer. Thyroid. 2001;11(12):1161-8.
8. Raue KF, Rondot S, Raue F. Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC. Molecular and Cellular Endocrinology. 2010;332:2-7.
9. Pitt SC, Chen H. The phosphatidylinositol 3-kinase/akt signaling pathway in medullary thyroid cancer. Surgery. 2008;144(5):721-4.
10. Runeberg-Roos P, Saarma M. Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases. Annals of Medicine. 2007;39(8):572-80.
11. Pierotti MA, Santoro M, Jenkins RB, et al. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci U S A. 1992;89(5):1616-20.
12. Lodish MB, Stratakis CA. RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert Rev Anticancer Ther. 2008;4: 625-32.
13. Burnichon N, Vescovo L, Amar L, et al. Gimenez-Roqueplo AP. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet. 2011;20(20):3974-85.
14. Angrist M, Bolk S, Halushka M, Lapchak PA, Chakravarti A. Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a Hirschsprung disease patient. Nat Genet. 1996;14(3):341-4.
15. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
16. Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L, Maia AL. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid. 2010;20(8):863-71.
17. Rodríguez-Antona C, Pallares J, Montero-Conde C, et al. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer. 2010;17(1):7-16.
18. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology. Curr Opin Oncol. 2001;13(6):506-13.
19. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169-81.
20. Ohgaki H. Genetic pathways to glioblastomas. Neuropathology. 2005; 25(1):1-7.
21. Lee DH, Lee GK, Kong SY, et al. Epidermal growth factor receptor status in anaplastic thyroid carcinoma. J Clin Pathol. 2007;60(8):881-4.
22. Chen BK, Ohtsuki Y, Furihata M, et al. Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage. Int J Oncol. 1999;15(5):893-8.
23. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002;62(24):7284-90.
24. Vitagliano D, De Falco V, Tamburrino A, et al. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer. 2010;18(1):1-11.
25. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res. 2003;9(4):1546-56.
26. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol. 2005;16(8):1391-7.
27. Tamura T, Minami H, Yamada Y, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol. 2006;1(9):1002-9.
28. Martin P, Oliver S, Kennedy SJ, et al. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin Ther. 2012;34(1):221-37.
29. Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole. Drugs R D. 2011;11(1):37-51.
30. Weil A, Martin P, Smith R, et al. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment. Clin Pharmacokinet. 2010;49(9):607-18.
31. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002;62(16):4645-55.
32. Zhang L, Li S, Zhang Y, et al. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. Clin Ther. 2011;33(3):315-27.
33. Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28(5):767-72.
34. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. Jun 2010;95(6):2664-71.
35. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134-41.
36. FDA. "News and Events. " FDA Approves New Treatment for Rare Form of Thyroid Cancer. FDA [Apr 6, 2011]. Web [Feb 27, 2012]. http://www.fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm250168.htm.
37. Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoS One. 2012;7(2):e30353.
38. Rosen AC, Wu S, Damse A, Sherman E, Lacouture ME. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab. Feb 29, 2012.
39. Yoon J, Oh CW, Kim CY. Stevens-johnson syndrome induced by vandetanib. Ann Dermatol. 2011;23(Suppl 3):S343-5.
40. Duplomb S, Benoit A, Mechtouff-Cimarelli L, et al. Unusual adverse event with vandetanib in metastatic medullary thyroid cancer. J Clin Oncol. 2012; 30(2):e21-3.
41. Nicholson SC, Peterson J, Yektashenas B. Risk evaluation and mitigation strategies (REMS): educating the prescriber. Drug Saf. 2012;35(2): 91-104.
42. FDA. Approved Risk Evaluation and Mitigation Strategies (REMS). FDA [Jun 22, 2011]. Web [Apr 5, 2012]. http://www.fda.gov/downloads/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ UCM253441.pdf.
43. Timmers L, Beckeringh JJ, Herk-Sukel MP, Boven E, Hugtenburg JG. Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008. Pharmacoepidemiol Drug Saf. 2011. doi: 10.1002/pds.2225.
44. Blanke CD, Huse D. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors. Journal of Medical Economics. 2010;13(4):681-90.
45. Verbeek HH, Alves MM, de Groot JW, et al. The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab. 2011;96(6):E991-5.
46. Leboulleux S, Bastholt L, Krause TM, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomized, double-blind phase II trial. Ann Oncol. 2010;21(Suppl 8):viii 315 (abstr 1008PD).
47. Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res. 2004;10(2):784-93.
48. Naumov GN, Nilsson MB, Cascone T, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res. 2009;15(10):3484-94.
49. Natale RB, Bodkin D, Govindan R, et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a twopart, double-blind, randomized phase II study. J Clin Oncol. 2009;27(15): 2523-9.
50. Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced nonsmall-cell lung cancer. J Clin Oncol. 2011;29(8):1059-66.
51. Lee JS, Hirsh V, Park K, et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol. 2012;30(10): 1114-21.
52. Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-smallcell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010;11(7):619-26.
53. De Boer RH, Arrieta Ó, Yang CH, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2011;29(8):1067-74.
54. Atalay G, Cardoso F, Awada A, Piccart MJ. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol. 2003;14(9):1346-63.
55. Miller KD, Trigo JM, Wheeler C, et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res. May 1, 2005;11(9): 3369-76.
56. Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, Mandal M. ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells. J Cell Physiol. 2011;226(2):375-84.
57. Boér K, Láng I, Llombart-Cussac A, et al. Vandetanib with docetaxel as secondline treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized phase II study. Invest New Drugs. 2012;30(2):681-7.
58. Cabebe EC, Fisher GA, Sikic BI. A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. Invest New Drugs. Mar 15, 2011.
59. Saunders MP, Wilson R, Peeters M, et al. Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre phase I study. Cancer Chemother Pharmacol. 2009;64(4):665-72.
60. Michael M, Gibbs P, Smith R, Godwood A, Oliver S, Tebbutt N. Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer. Invest New Drugs. 2009;27(3):253-61.
61. Hsu C, Yang TS, Huo TI, et al. Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebocontrolled study. J Hepatol. Jan 13, 2012.
62. Horti J, Widmark A, Stenzl A, et al. A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother Radiopharm. 2009;24(2):175-80.
63. Choueiri TK, Ross RW, Jacobus S, et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinumpretreated metastatic urothelial cancer. J Clin Oncol. 2012;30(5):507-12.
64. Saletti P, Sessa C, De Dosso S, Cerny T, Renggli V, Koeberle D. Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma. Oncology. 2011;81(1):50-4.